Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Atara Biotherapeutics (ATRA) Treasury Shares (2022 - 2025)

Atara Biotherapeutics' Treasury Shares history spans 4 years, with the latest figure at $216048.0 for Q4 2025.

  • For Q4 2025, Treasury Shares fell 47.87% year-over-year to $216048.0; the TTM value through Dec 2025 reached $216048.0, down 47.87%, while the annual FY2025 figure was $216048.0, 47.87% down from the prior year.
  • Treasury Shares reached $216048.0 in Q4 2025 per ATRA's latest filing, down from $278347.0 in the prior quarter.
  • In the past five years, Treasury Shares ranged from a high of $16.5 million in Q1 2024 to a low of $216048.0 in Q4 2025.
  • Average Treasury Shares over 4 years is $4.9 million, with a median of $3.7 million recorded in 2022.
  • Peak YoY movement for Treasury Shares: tumbled 96.26% in 2023, then skyrocketed 65.32% in 2024.
  • A 4-year view of Treasury Shares shows it stood at $6.7 million in 2022, then crashed by 96.26% to $250709.0 in 2023, then surged by 65.32% to $414470.0 in 2024, then crashed by 47.87% to $216048.0 in 2025.
  • Per Business Quant, the three most recent readings for ATRA's Treasury Shares are $216048.0 (Q4 2025), $278347.0 (Q3 2025), and $503640.0 (Q2 2025).